---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-041333"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2026-09-03T15:45:15+00:00"
generated_at: "2026-09-03T15:46:13.472819+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma effects 1-for-25 reverse stock split, cuts authorized shares to 26.5M

## Summary
- Reverse split effective 12:01 a.m. ET Sept 8, 2026; trading on split-adjusted basis begins at market open.
- Outstanding shares drop from ~45,109,497 to ~1,804,379; no fractional shares, cash paid for fractions.
- Authorized capital reduced from 265M to 26.5M shares (25M common, 1.5M preferred); new CUSIP 36254L407.
- Certificates of Elimination filed for Series A-K preferred; all Series C converted, no other preferred outstanding.
- Board approved 1-for-25 ratio on Aug 27, 2026, following stockholder authorization at Aug 14 meeting.

## SEC filing metadata
- accession: 0001493152-26-041333
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2026-09-03T15:45:15+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315226041333/0001493152-26-041333-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315226041333/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-041333
- JSON: https://secwatch.observer/filing/0001493152-26-041333.json
- Plain text: https://secwatch.observer/filing/0001493152-26-041333.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.